VIR Vir Biotechnology Inc.

18.96
+2.7  (+17%)
Previous Close 16.26
Open 18
Price To Book -7.41
Market Cap 2,079,510,465
Shares 109,678,822
Volume 740,860
Short Ratio
Av. Daily Volume 388,219
Stock charts supplied by TradingView

NewsSee all news

  1. Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference

    SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  2. Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

    SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  3. Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

    SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing

  4. Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent

  5. Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies

    CALGARY and SYDNEY, Jan. 9, 2020 /CNW/ - Sundial Growers Inc. (NASDAQ:SNDL) ("Sundial"), a Canadian licensed cannabis producer and Vir Pharma Holdings Pty Ltd.  (NASDAQ:VIR) ("Vir Pharma"), an Australian

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 additional data due 1H 2020.
ALN-HBV02 (VIR-2218)
Chronic hepatitis B virus (HBV)
Phase 2 data due 2H 2020.
VIR-2482
Influenza

Latest News

  1. Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference

    SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  2. Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

    SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  3. Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

    SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing

  4. Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent

  5. Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies

    CALGARY and SYDNEY, Jan. 9, 2020 /CNW/ - Sundial Growers Inc. (NASDAQ:SNDL) ("Sundial"), a Canadian licensed cannabis producer and Vir Pharma Holdings Pty Ltd.  (NASDAQ:VIR) ("Vir Pharma"), an Australian

  6. Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent

  7. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  8. Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent